FDA Approves New Treatment for Thyroid Eye Disease - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.

  • By

  • Kathryn Wighton

  • June 29, 2026

  • 3 min

Share

Original Source(s)

FDA Approves New Treatment for Thyroid Eye Disease

  • by Kathryn Wighton

  • June 29, 2026

Related Content

ACP Ranks Obesity Drug Options

A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.

NEJM Retracts Avacopan Vasculitis Study

"The primary end-point assessments in nine patients were readjudicated after database lock and trial unblinding"

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.